Switzerland (CH)

Reduction in Nuclear Size and Quadrupole Deformation of High-Spin Isomers of ^{127,129}In (2025) Vernon AR, Binnersley CL, Ruiz RF, Lynch KM, Miyagi T, Billowes J, Bissell ML, et al. Journal article Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations (2025) Untch M, Banys-Paluchowski M, Brucker SY, Denkert C, Fasching P, Haidinger R, Harbeck N, et al. Journal article, Review article Machine Learning Predictions of Overall and Progression-Free Survival in Advanced Breast Cancer (2025) Merzhevich T, Tanzanakis A, Salin E, Quiering C, Kurz C, Gmeiner B, Eskofier B Conference contribution Control of Buckling of Colloidal Supraparticles (2025) Römling L, De Angelis G, Mauch A, Amstad E, Vogel N Journal article Notfallpharmakologische Relevanz der EMA-Warnmeldung zu Metamizol (2025) Heinmann A, Ittner KP, Koppenberg J, Mansberger P, Neubert A, Prückner S, Walter U Journal article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial (2025) Gani C, Fokas E, Polat B, Ott O, Diefenhardt M, Königsrainer A, Böke S, et al. Journal article From homemakers to breadwinners? How mandatory kindergarten affects maternal labour market outcomes (2025) Gangl S, Huber M Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article